scholarly journals Insulin-like growth factor 2 mRNA-binding protein 2-stabilized long non-coding RNA Taurine up-regulated gene 1 (TUG1) promotes cisplatin-resistance of colorectal cancer via modulating autophagy

Bioengineered ◽  
2022 ◽  
Vol 13 (2) ◽  
pp. 2450-2469
Author(s):  
Cuifeng Xia ◽  
Qiang Li ◽  
Xianshuo Cheng ◽  
Tao Wu ◽  
Pin Gao ◽  
...  
2017 ◽  
Vol 152 (5) ◽  
pp. S106
Author(s):  
Kathy N. Williams ◽  
Sarah F. Andres ◽  
Ranjan Preet ◽  
Kathryn E. Hamilton ◽  
Priya Chatterji ◽  
...  

2021 ◽  
Vol 22 (13) ◽  
pp. 6940
Author(s):  
Hung-Ming Chen ◽  
Chun-Chi Lin ◽  
Wei-Shone Chen ◽  
Jeng-Kai Jiang ◽  
Shung-Haur Yang ◽  
...  

Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an RNA-binding protein and serves as a post-transcriptional fine-tuner regulating the expression of mRNA targets. However, the clinicopathological roles of IGF2BP1 in colorectal cancer (CRC) remains limited. Thus, we aimed to elucidate the clinical significance and biomarker potentials of IGF2BP1 in CRC. A total of 266 specimens from two sets of CRC patients were collected. IGF2BP1 expression was studied by immunohistochemical (IHC) staining. The Kaplan-Meier survival plot and a log-rank test were used for survival analysis. The Cox proportional hazards model was applied to determine the survival impact of IGF2BP1. Public datasets sets from The Cancer Genome Atlas (TCGA) and Human Cancer Metastasis Database (HCMDB), receiver operating characteristic (ROC) plotter, and two CRC cell lines, HCT-116 and DLD-1, were used for validating our findings. We showed that IGF2BP1 was overexpressed in tumor specimens compared to 13 paired normal parts by examining the immunoreactivity of IGF2BP1 (p = 0.045). The increased expression of IGF2BP1 in primary tumor parts was observed regardless of metastatic status (p < 0.001) in HCMDB analysis. IGF2BP1 expression was significantly associated with young age (59.6% vs. 46.7%, p-value = 0.043) and advanced stage (61.3% vs. 40.0%, p-value = 0.001). After controlling for confounding factors, IGF2BP1 remained an independent prognostic factor (HR = 1.705, p-value = 0.005). TCGA datasets analysis indicated that high IGF2BP1 expression showed a lower 5-year survival rate (58% vs. 65%) in CRC patients. The increased expression of IGF2BP1 in chemotherapy non-responder rectal cancer patients was observed using a ROC plotter. Overexpression of IGF2BP1 promoted the colony-forming capacity and 5-fluorouracil and etoposide resistance in CRC cells. Here, IGF2BP1 was an independent poor prognostic marker in CRC patients and contributed to aggressive phenotypes in CRC cell lines.


2018 ◽  
Vol 11 (1) ◽  
Author(s):  
Xinwei Huang ◽  
Hong Zhang ◽  
Xiaoran Guo ◽  
Zongxin Zhu ◽  
Haibo Cai ◽  
...  

2013 ◽  
Vol 69 (2) ◽  
pp. e20-e21
Author(s):  
Chia-Yu Chu ◽  
Yi-Shuan Sheen ◽  
Kuanyin K. Lin ◽  
Meng-Chen Hsieh ◽  
Hsien-Ching Chiu ◽  
...  

2020 ◽  
Vol 10 ◽  
Author(s):  
Caterina Mancarella ◽  
Giulia Caldoni ◽  
Irene Ribolsi ◽  
Alessandro Parra ◽  
Maria Cristina Manara ◽  
...  

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiao-Han Cui ◽  
Shu-Yi Hu ◽  
Chun-Fu Zhu ◽  
Xi-Hu Qin

Abstract Background Despite advances in early diagnosis and treatment, cancer remains the leading cause of mortality worldwide. The insulin-like growth factor 2 mRNA binding protein (IGF2BP) family has been reported to be involved in a variety of human malignant tumours. However, little is known about their expression and prognostic value in human pancreatic cancer. Therefore, we performed a detailed cancer versus normal differential analysis. Methods The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases were used to analyse the mRNA expression levels of the IGF2BP family in various cancers, including pancreatic cancer. Then, the LinkedOmics and GEPIA databases were used to assess the relation between the expression levels of IGF2BPs and overall survival (OS). Then, univariate and multivariate Cox regression analyses were performed, and subgroups based on grade and stage were analysed. The signalling pathways associated with IGF2BP2 and IGF2BP3 were then investigated via gene set enrichment analysis (GSEA). Results IGF2BP2 and IGF2BP3 were associated with each subset of OS based on grade and stage. Further clinical correlation analysis of IGF2BP2 and IGF2BP3 confirmed that IGF2BP2 and IGF2BP3 are fundamental factors in promoting pancreatic cancer progression. Conclusion IGF2BP2 and IGF2BP3 are key factors in promoting the progression of pancreatic cancer and are closely related to overall survival.


Sign in / Sign up

Export Citation Format

Share Document